?What makes our approach different? #EpigenomicControllers are programmed to target unique sequences within the genome with high specificity to controllably tune gene expression for a tailored duration. They are designed to overcome the compensatory autoregulation often associated with key disease drivers, including those historically undruggable with conventional approaches. Learn more here: https://bit.ly/3xiJzZo
Omega Therapeutics
生物技术研究
Cambridge，Massachusetts 16,588 位关注者
Pioneering the first systematic approach to using mRNA as a new class of programmable epigenomic medicines.
关于我们
Omega Therapeutics is a clinical-stage biotechnology company pioneering the first systematic approach of using mRNA as programmable epigenomic medicines. Our OMEGA platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism's life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega’s engineered, modular, and programmable mRNA medicines, Omega Epigenomic Controllers?, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through unprecedented precision epigenomic control. Omega has a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.
- 网站
-
https://www.omegatherapeutics.com
Omega Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2017
地点
-
主要
获取路线
20 Acorn Park Dr
STE 400
US，Massachusetts，Cambridge，02140
Omega Therapeutics员工
动态
-
Wishing all our #Omegans and their families a healthy, joyful, and peaceful holiday season! Thank you for your hard work, dedication, and passion throughout the year.
-
-
In case you missed it, we shared a poster at the American Association for the Study of Liver Diseases (AASLD)'s #TLM24 showcasing durable upregulation of HNF4α using an #EpigenomicController (EC). ECs precisely tune genetic expression by site-specifically modulating epigenetic state. This represents a potentially novel therapeutic strategy for the treatment of fibrotic liver disease. View the poster here: https://bit.ly/4eVuSeF
-
Currently available #obesity treatments focus on appetite management and may not be effective for every patient. At Omega, we are partnering with Novo Nordisk to potentially reimagine obesity treatment using an #EpgenomicController. Read more about our partnership here: https://bit.ly/4cgF53K
-
-
At Omega, we’re grateful for our dedicated team working to advance innovative #EpigenomicControllers for patients in need. We deeply appreciate the passion of our #Omegans and the values that drive us. #OmegaValues
-
-
We are driven by our mission to develop novel therapies to treat and potentially cure serious diseases using our OMEGA platform. This month at the 12th International #mRNAHealthConference and the American Association for the Study of Liver Diseases (AASLD)’s The Liver Meeting?, we presented exciting preclinical data showcasing durable upregulation of #GeneExpression by our #EpigenomicControllers. Learn more about the data here: https://bit.ly/4fAkPMY
-
-
Today we announced our Third Quarter 2024 financial results, completion of our Phase 1 study and strategic updates. Learn more in our press release: https://bit.ly/3URA77S
-
-
At #SITC2024, we presented a poster highlighting that controlled epigenomic upregulation of CXCL9 & CXCL10 in #HepatocellularCarcinoma promotes T-cell recruitment. These data exemplify the versatile capabilities of the OMEGA platform. Learn more here: https://bit.ly/491M6FX
-
-
Epigenetic modifications, or reversible modifications on top of #DNA or its scaffolding, control the winding of DNA’s 3D loops without altering underlying sequences. Our OMEGA platform leverages our understanding of genomic architecture to design therapeutic candidates that act pre-transcriptionally to control gene expression. Learn more about our science here: https://bit.ly/4couGU9
-
-
What sets the OMEGA Platform apart? ?? #EpigenomicControllers are highly specific in targeting to control up or down expression of single or multiple genes ?? Customizable delivery takes advantage of both existing and emerging modalities tailored to the characteristics of a specific disease ?? Modular and AI-driven approach enables rapid design and development of candidates, accelerating optimization and preclinical development Learn more here: https://bit.ly/3zsae6I
-